|
FDA Grants Accelerated Review For Pfizer Cancer Drug
Automated Trader The fusion of ALK with another gene is believed to be present in about 3% to 5% of people with non-small cell lung cancer, or 40000 patients diagnosed annually worldwide. Pfizer has proposed to market the drug for the treatment of ALK-positive advanced … Pfizer Files NDA For Lung Cancer Drug Crizotinib With FDA, Japan – Update Pfizer's Application for Cancer Drug Accepted by FDA Pfizer cancer drug takes big step toward fateful FDA decision |
View full post on lung cancer – Google News
